Total raised
BYN 32 525,48
Total raised (%)
Nazar Bobekh
Nazar Bobekh
09/30/2015, city of Mazyr, Gomel region

Nazar Bobekh

30.09.2015, city of Mazyr, Gomel region
  • Diagnosis: neuroblastoma
Fundraising is over
Meet the child
The disease manifested itself in the summer of 2019. Since August, Nazar is undergoing a treatment according to the protocol in the Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany. The kid is undergoing complex antitumor treatment successfully including MIBG therapy at the Russian Scientific Center of Roentgenology & Radiology of the Ministry of Health Russian Federation.

MIBG therapy is an up-and-coming treatment for advanced-stage neuroblastoma. Current treatment options including chemotherapy, surgery, radiation therapy, and stem cell transplantation are powerful, but not powerful enough. New therapeutic options are needed. MIBG is a molecule that is readily absorbed by neuroblastoma cells. MIBG can be a safer therapy than traditional radiation therapy, as it delivers the radiation directly to the tumor and minimizes exposure to healthy tissues. Additionally, it can radiate metastatic tumors throughout the body in one treatment, which is much more difficult with traditional radiation therapy. Therapy is scheduled for February 6, 2020.

In 2019 the MIBG-scintigraphy was paid for the boy’s treatment. Funds were transferred by the general partner of the Gazprom Transgaz Belarus Fund under the program “Providing of medical assistance for children with oncological diseases program”.

To consolidate the results and to avoid recurrence of the disease, anti-GD2 antibody-containing immunotherapy was recommended. Effective immunotherapy holds particular promise for improving survival and quality of life, it is possible to achieve very good results in the treatment of neuroblastoma. An expensive drug Dinutuximab beta is required for the procedure.

Dear benefactors!
On the basis of the petition of the Republican Scientific and Practical Center for Pediatric Oncology, Hematology and Immunology and the decision of the Foundation Board dated January 21, 2021 No. 2, the drug purchased for Nazar Bobekh will be redirected for the treatment of Alisa Panteleeva.

As of 02/03/2021, the foundation did not receive applications for the return of targeted donations for Bobekh Nazar. Thus, our foundation redirects the drug Dinutuximab-beta (Quarziba) for the treatment of Alisa Panteleeva.

Dear friends, thank you for supporting Nazar!
Together we make a difference!
  • Diagnosis: oncological, hematological and immunological diseases
  • Fundraising goal: medications, MIBG-diagnostic, FMI-test
Amount needed
535 000
We still need to raise
296 622
Total raised (%)